Literature DB >> 7539459

The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.

M Sebbag1, M Simon, C Vincent, C Masson-Bessière, E Girbal, J J Durieux, G Serre.   

Abstract

The so-called antikeratin antibodies (AKA) and the antiperinuclear factor (APF) are the most specific serological markers of RA. Using indirect immunofluorescence, AKA label the stratum corneum of various cornified epithelia and APF the keratohyalin granules of human buccal mucosa epithelium. We recently demonstrated that AKA recognize human epidermal filaggrin. Here, we report the identification of the major APF antigen as a diffuse protein band of 200-400 kD. This protein is seen to be closely related to human epidermal (pro) filaggrin since it was recognized by four antifilaggrin mAbs specific for different epitopes, and since the APF titers of RA sera were found to be correlated to their AKA titers and to their immunoblotting reactivities to filaggrin. Immunoabsorption of RA sera on purified epidermal filaggrin abolished their reactivities to the granules of buccal epithelial cells and to the 200-400-kD antigen. Moreover, antifilaggrin autoantibodies, i.e., AKA, affinity purified from RA sera, were shown to immunodetect the 200-400-kD antigen and to stain these granules. These results indicate that AKA and APF are largely the same autoantibodies. They recognize human epidermal filaggrin and (pro) filaggrin-related proteins of buccal epithelial cells. Identification of the epitopes recognized by these autoantibodies, which we propose to name antifilaggrin autoantibodies, will certainly open new paths of research into the pathophysiology of RA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539459      PMCID: PMC295950          DOI: 10.1172/JCI117969

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Characterization of two monoclonal antibodies to human epidermal keratohyalin: reactivity with filaggrin and related proteins.

Authors:  B A Dale; A M Gown; P Fleckman; J R Kimball; K A Resing
Journal:  J Invest Dermatol       Date:  1987-03       Impact factor: 8.551

2.  Immunologic localization of filaggrin in human oral epithelia and correlation with keratinization.

Authors:  S A Smith; B A Dale
Journal:  J Invest Dermatol       Date:  1986-02       Impact factor: 8.551

3.  Antikeratin antibodies in rheumatoid arthritis. Methods and clinical significance.

Authors:  H Kirstein; F K Mathiesen
Journal:  Scand J Rheumatol       Date:  1987       Impact factor: 3.641

4.  Anti-perinuclear and rheumatoid factor in different forms of autoimmune thyroid disease.

Authors:  W A Scherbaum; P Y Youinou; P Le Goff; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

5.  Significance of antikeratin antibodies in rheumatoid arthritis.

Authors:  V J Hajiroussou; J Skingle; A P Gillett; M Webley
Journal:  J Rheumatol       Date:  1985-02       Impact factor: 4.666

6.  Anticytoskeletal autoantibodies in the connective tissue diseases.

Authors:  J L Senécal; J M Oliver; N Rothfield
Journal:  Arthritis Rheum       Date:  1985-08

7.  Cell type heterogeneity of cytokeratin expression in complex epithelia and carcinomas as demonstrated by monoclonal antibodies specific for cytokeratins nos. 4 and 13.

Authors:  G N van Muijen; D J Ruiter; W W Franke; T Achtstätter; W H Haasnoot; M Ponec; S O Warnaar
Journal:  Exp Cell Res       Date:  1986-01       Impact factor: 3.905

8.  Antikeratin antibodies in serum and synovial fluid show specificity for rheumatoid arthritis in a study of connective tissue diseases.

Authors:  P Youinou; P Le Goff; C B Colaco; J Thivolet; D Tater; J Viac; M Shipley
Journal:  Ann Rheum Dis       Date:  1985-07       Impact factor: 19.103

9.  Prospect for an additional laboratory criterion for rheumatoid arthritis.

Authors:  R von Essen; P Kurki; H Isomäki; S Okubo; H Kautiainen; K Aho
Journal:  Scand J Rheumatol       Date:  1993       Impact factor: 3.641

10.  Anti-intermediate filament antibodies, antikeratin antibody, and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis.

Authors:  P K Kataaha; S M Mortazavi-Milani; G Russell; E J Holborow
Journal:  Ann Rheum Dis       Date:  1985-07       Impact factor: 19.103

View more
  84 in total

1.  Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome.

Authors:  J-E Gottenberg; S Mignot; P Nicaise-Rolland; J Cohen-Solal; F Aucouturier; J Goetz; C Labarre; O Meyer; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2004-07-01       Impact factor: 19.103

2.  Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis.

Authors:  David C Wilson; Anthony D Marinov; Harry C Blair; Daniel S Bushnell; Susan D Thompson; Yury Chaly; Raphael Hirsch
Journal:  Arthritis Rheum       Date:  2010-08

Review 3.  Biomarkers to guide clinical therapeutics in rheumatology?

Authors:  William H Robinson; Rong Mao
Journal:  Curr Opin Rheumatol       Date:  2016-03       Impact factor: 5.006

4.  Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease.

Authors:  K Skriner; W H Sommergruber; V Tremmel; I Fischer; A Barta; J S Smolen; G Steiner
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF.

Authors:  I G Silveira; R W Burlingame; C A von Mühlen; A L Bender; H L Staub
Journal:  Clin Rheumatol       Date:  2007-04-05       Impact factor: 2.980

Review 6.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

Review 7.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

Review 8.  The pathogenic potential of autoreactive antibodies in rheumatoid arthritis.

Authors:  Marieke Bax; Tom W J Huizinga; René E M Toes
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

9.  A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population.

Authors:  L Caponi; E Petit-Teixeira; M Sebbag; F Bongiorni; S Moscato; F Pratesi; C Pierlot; J Osorio; S Chapuy-Regaud; M Guerrin; F Cornelis; G Serre; P Migliorini
Journal:  Ann Rheum Dis       Date:  2004-10-14       Impact factor: 19.103

10.  Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma.

Authors:  M Labrador; A Algueró; C Díaz; C Geli; E Pérez; J García-Valero; J L Rodriguez-Sanchez; C Gelpí
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.